AWT032

About Anwita Biosciences

Anwita Biosciences is a private, clinical-stage biotech leveraging an integrated technology platform for protein engineering to develop novel immunotherapies and targeted oncology treatments. Its lead asset, AWT020 (an anti-PD-1-IL-2 fusion protein), is in Phase 1 trials and has received FDA Orphan Drug Designation for thymic epithelial tumors. The company's strategy combines a deep biological understanding with rational engineering for selectivity and safety, supported by strategic partnerships and venture financing to advance its pipeline.

Therapeutic Areas